By inhibiting IL‐23 and IL‐17, Guselkumab effectively alleviates intestinal inflammation in patients with ulcerative colitis (UC) [77], reducing symptoms such as diarrhea, abdominal pain, and rectal bleeding, thereby enhancing their quality of life [78]. The gene discussed is IL17A; the disease is ulcerative colitis.